CTI BioPharma to Report First Quarter 2022 Financial Results on May 12, 2022

Rhea-AI Summary

CTI BioPharma Corp. (NASDAQ: CTIC) will report its first quarter 2022 financial results on May 12, 2022, after U.S. market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss the results and corporate updates. The company focuses on targeted therapies for blood-related cancers, with one FDA-approved product, VONJO™, for specific myelofibrosis patients. VONJO™ is currently part of the Phase 3 PACIFICA study as a post-marketing requirement.

Positive

• The company has one FDA-approved product, VONJO™, for myelofibrosis.
• Ongoing Phase 3 PACIFICA study of VONJO™ indicates continued product development.

Negative

• None.

SEATTLE, April 28, 2022 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its first quarter 2022 financial results on Thursday, May 12, 2022, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a conference call and webcast to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT).

To access the live call by phone please dial (877) 735-2860 (domestic) or (602) 563-8791 (international); the conference ID is 7291915. A live audio webcast of the event may also be accessed through the "Investors" section of CTI's website at www.ctibiopharma.com. A replay of the webcast will be available for 30 days following the event.

About CTI BioPharma Corp.
We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJO™ (pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10⁹/L. CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.

VONJO™ is a trademark of CTI BioPharma Corp.

CTI BioPharma Investor Contacts: 
Argot Partners 
+212-600-1902 
cti@argotpartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-to-report-first-quarter-2022-financial-results-on-may-12-2022-301535837.html

SOURCE CTI BioPharma Corp.

FAQ

When is CTI BioPharma's first quarter 2022 earnings announcement?

CTI BioPharma will announce its first quarter 2022 earnings on May 12, 2022.

What time will the CTI BioPharma conference call take place?

The conference call will take place at 4:30 p.m. ET on May 12, 2022.

What is VONJO™ used for?

VONJO™ is used for treating adults with intermediate or high-risk myelofibrosis.

What is the PACIFICA study in relation to CTI BioPharma?

The PACIFICA study is a Phase 3 trial of VONJO™ for patients with myelofibrosis and severe thrombocytopenia.